Phase 2 Clinical Trial of Retatrutide, Triple Hormone-Receptor Agonist, bakeng sa Phekolo ea Botenya

Moralo oa Moralo le Boithuto

Retatrutide (LY3437943) ke sethethefatsi se seng sa peptide se sebetsang.li-receptor tse tharo ka nako e le 'ngoe: GIP, GLP-1, le glucagon. Ho lekola katleho ea eona le polokeho ho batho ba nang le botenya empa ba se na lefu la tsoekere, ho ile ha etsoa teko ea mohato oa 2, e sa sebetseng, e sa boneng habeli, e laoloang ke placebo (NCT04881760). Kakaretso ea338 barupeluoae nang le BMI ≥30, kapa ≥27 bonyane e amanang le boima ba 'mele bo amanang le boima ba' mele, e ile ea etsoa ka mokhoa o sa reroang ho amohela placebo kapa retatrutide (1 mg, 4 mg e nang le lipampiri tse peli tsa titration, 8 mg ka lipampiri tse peli tsa titration, kapa 12 mg) e tsamaisoang hang ka beke ka ente ea subcutaneous bakeng sa libeke tsa 48. Thentlha ea mantlhae ne e le phetoho ea peresente ea boima ba 'mele libekeng tsa 24, ka liphetho tsa bobeli tse kenyelletsang ho fetoha ha boima ba' mele libeke tsa 48 le menyako ea ho theola boima ba 'mele (≥5%, ≥10%, ≥15%).

Liphetho tsa bohlokoa

• Libeke tse 24: Bonyane-squares bolela liphesente phetoho boima ba 'mele ho ea ka motheo e ne e

  • Sebaka: −1.6%

  • 1 mg: -7.2%

  • 4 mg (e kopantsoe): −12.9%

  • 8 mg (e kopantsoe): -17.3%

  • 12 mg: -17.5%

• Libeke tse 48: Phetoho ea peresente ea boima ba 'mele e ne e

  • Sebaka: −2.1%

  • 1 mg: -8.7%

  • 4 mg (e kopantsoe): -17.1%

  • 8 mg (e kopantsoe): -22.8%

  • 12 mg: -24.2%

Libekeng tse 48, palo ea barupeluoa ba fihletseng litekanyo tsa ho theola boima ba 'mele e ne e hlolla:

• ≥5% tahlehelo ea boima ba 'mele: 27% e nang le placebo vs. 92-100% ka lihlopha tse sebetsang

• ≥10%: 9% e nang le placebo vs. 73-93% ka lihlopha tse sebetsang

• ≥15%: 2% e nang le placebo vs. 55-83% ka lihlopha tse sebetsang

Sehlopheng sa 12 mg, ho fihlela ho26% ea barupeluoa ba lahlehetsoe ke ≥30% ea boima ba bona ba motheo, boholo ba boima ba 'mele bo bapisoang le ho buuoa ka bariatric.

Polokeho
Liketsahalo tse mpe tse atileng haholo e ne e le mala a ka mpeng (ho nyekeloa ke pelo, ho hlatsa, letšollo), hangata a bobebe ho isa ho a itekanetseng le a amanang le tekanyetso. Litekanyetso tse tlase tsa ho qala (2 mg titration) li fokolitse liketsahalo tsena. Keketseho e amanang le tekanyo ea tekanyo ea pelo e ile ea hlokomeloa, ho phahama ka beke ea 24, ebe e fokotseha. Litefiso tsa ho khaotsa ho tloha ho 6-16% ho pholletsa le lihlopha tse sebetsang, tse batlang li phahame ho feta placebo.

Liqeto
Ho batho ba baholo ba nang le botenya ntle le lefu la tsoekere, beke le beke subcutaneous retatrutide bakeng sa libeke tse 48 e hlahisoaphokotso e kholo, e itšetlehileng ka tekanyo ea boima ba 'mele(ho fihlela ~ 24% e bolela tahlehelo ka tekanyo e phahameng ka ho fetisisa), hammoho le ntlafatso ea matšoao a cardiometabolic. Liketsahalo tse mpe tsa ka mpeng li ne li etsahala khafetsa empa li ne li laoleha ka mokhoa oa titration. Liphuputso tsena tsa mohato oa 2 li fana ka maikutlo a hore retatrutide e ka emela benchmark e ncha ea phekolo bakeng sa botenya, e emetse ho tiisoa litekong tse khōloanyane, tsa nako e telele tsa 3.